Treatment of diabetes in patients with severe obesity

被引:21
作者
Scheen, AJ [1 ]
机构
[1] CHU Sart Tilman, Dept Med, Div Diabet Nutr & Metab Disorders, B-4000 Liege 1, Belgium
关键词
management; obesity; type; 2; diabetes;
D O I
10.1016/S0753-3322(00)88855-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Besides genetic predisposition, obesity is the most important risk factor for the development of diabetes mellitus, and weight reduction has been shown to markedly improve blood glucose control in obese subjects with type 2 diabetes. Therapeutic strategies for the obese diabetic patient include: 1) promoting weight loss through Lifestyle modifications (hypocaloric diet and exercise) and anti-obesity drugs (orlistat, sibutramine, etc.); 2) improving blood glucose control, essentially through the reduction of insulin resistance (metformin: eventually thiazolidinediones) or insulin need (alpha-glucosidase inhibitors) and, at a later stage, the correction of defective insulin secretion (sulphonylureas, repaglinide) or low circulating insulin levels (exogenous insulin); and 3) treating common associated risk factors, such as arterial hypertension and dyslipidnemias, to improve cardiovascular prognosis. When morbid obesity is present, both restoring a good glycemic control and correcting associated risk factors can only be obtained through marked and sustained weight loss. This primary objective justifies more aggressive weight reduction programmes, including very low-calorie diets and bariatric surgery, but only within a multidisciplinary approach and in well-selected patients. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:74 / 79
页数:6
相关论文
共 48 条
[1]  
[Anonymous], 1995, DIABETES CARE, V18, P1510
[2]   BIGUANIDES AND NIDDM [J].
BAILEY, CJ .
DIABETES CARE, 1992, 15 (06) :755-772
[3]  
Bosello O, 1997, INT J OBESITY, V21, pS10
[4]  
Bray GA, 1997, DIABETES REV, V5, P83
[5]   Promoting weight loss in type II diabetes [J].
Brown, SA ;
Winter, M ;
Upchurch, S ;
Ramirez, G ;
Anding, R .
DIABETES CARE, 1996, 19 (06) :613-624
[6]   An overview of metformin in the treatment of type 2 diabetes mellitus [J].
Davidson, MB ;
Peters, AL .
AMERICAN JOURNAL OF MEDICINE, 1997, 102 (01) :99-110
[7]   Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial [J].
Davidson, MH ;
Hauptman, J ;
DiGirolamo, M ;
Foreyt, JP ;
Halsted, CH ;
Heber, D ;
Heimburger, DC ;
Lucas, CP ;
Robbins, DC ;
Chung, J ;
Heymsfield, SB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03) :235-242
[8]   INSULIN RESISTANCE - A MULTIFACETED SYNDROME RESPONSIBLE FOR NIDDM, OBESITY, HYPERTENSION, DYSLIPIDEMIA, AND ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE [J].
DEFRONZO, RA ;
FERRANNINI, E .
DIABETES CARE, 1991, 14 (03) :173-194
[9]   METFORMIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
DUNN, CJ ;
PETERS, DH .
DRUGS, 1995, 49 (05) :721-749
[10]   Lifestyle modifications for diabetes management [J].
Franz, MJ .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1997, 26 (03) :499-&